8-K: PROCEPT BioRobotics Announces Prostate Cancer Initiative and Presents Clinical Data at AUA Annual Meeting

PROCEPT BioRobotics highlights its prostate cancer initiative and presents clinical data, including updates on the WATER IV trial and early data from PRCT001 and PRCT002, at the American Urological Association (AUA) Annual Meeting.

Summary

• PROCEPT BioRobotics is presenting at the American Urological Association Annual Meeting on April 25, 2025.
• The presentation includes updates on the HYDROS Robotic System and commercial progress.
• A key focus is the prostate cancer initiative, including the WATER IV trial comparing Aquablation to radical prostatectomy.
• Early data from the PRCT001 and PRCT002 studies, involving Grade Group 1-3 prostate cancer patients, are also presented.
• The company's key milestones include Medicare reimbursement, an IPO at a $1.2B market cap, and FDA clearance of the HYDROS System.
• Global revenue for 2024 was $224.5M, and revenue guidance for 2025 is $323M.
• The company expects to become the #2 hospital-based resective BPH procedure in the U.S.
• The HYDROS system is gaining traction with hospitals due to its streamlined workflow and potential for cost reduction.
• Dr. Gerald Park from Kansas City Urology & Oncology shared his experience of growing his BPH practice with Aquablation therapy, noting a 42% increase in annual BPH procedures since 2021.
• Aquablation is being investigated as a whole-gland treatment for prostate cancer, with the goal of delaying or preventing cancer progression.
• The WATER IV trial is a randomized study comparing Aquablation to prostatectomy for localized prostate cancer.
• Preliminary 6-month data from PRCT001 and PRCT002 show encouraging progress in erectile function and urinary incontinence compared to radical prostatectomy benchmarks.
• The company aims to provide a front-line treatment option for localized prostate cancer with Aquablation, maximizing both safety and efficacy.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for PROCEPT BioRobotics, highlighting strong revenue growth, successful product launches, and promising clinical data. The focus on innovation and expansion into prostate cancer treatment further contributes to the positive sentiment.

Positives

• The HYDROS system is resonating with all BPH hospital segments and driving market awareness.
• Legacy low/medium volume BPH hospitals are growing into high volume BPH hospitals.
• Aquablation allows surgeons to perform at a higher level with more precision vs. legacy procedures.
• Aquablation therapy is efficient, with predictable operating times and the ability to stack more cases.
• Preliminary data suggests Aquablation can significantly slow the progression of prostate cancer.
• Aquablation offers a superior safety profile compared to traditional resective procedures for BPH.

Risks

• The forward-looking statements are subject to risks and uncertainties, including market acceptance of AQUABEAM and HYDROS, payment policies, competition, regulatory approvals, and clinical trial outcomes.
• The company depends on a limited number of third-party suppliers.
• There are risks associated with maintaining intellectual property rights and avoiding infringement on third-party rights.

Future Outlook

The company anticipates continued growth and market penetration with the HYDROS system and expects to become the #2 hospital-based resective BPH procedure in the U.S. They are also focused on expanding the use of Aquablation therapy into prostate cancer treatment.

Management Comments

• Dr. Gerald Park believes Aquablation therapy is the only surgical option that will expand the market.
• Dr. Park believes automation and robotics are the future of medicine.
• Dr. Park believes Aquablation allows surgeons to perform at a higher level with more precision vs. legacy procedures.

Industry Context

This announcement positions PROCEPT BioRobotics as a key player in the evolving landscape of BPH and prostate cancer treatment, emphasizing minimally invasive robotic surgery and a focus on patient outcomes. The company is directly competing with established procedures like TURP and radical prostatectomy, while also exploring new applications for its Aquablation technology.

Comparison to Industry Standards

• The presentation references the PROTECT trial, AFU study, and TrueNTH study to benchmark Aquablation's performance against radical prostatectomy in terms of erectile function and urinary incontinence.
• The company compares Aquablation procedure times to other resective treatments like Greenlight PVP, ThuLEP, GreenLEP, and HoLEP, highlighting its efficiency.
• The presentation cites studies from UCL London and Case Western to compare upgrade rates in active surveillance for prostate cancer with the results observed in Aquablation patients.
• The company references the WATER III trial to demonstrate the volume reduction achieved by Aquablation, which is approximately 50%.

Stakeholder Impact

• Shareholders can expect continued growth and potential for increased market value.
• Employees may benefit from the company's expansion and success.
• Patients may have access to a less invasive and more effective treatment option for BPH and prostate cancer.
• Hospitals may benefit from the HYDROS system's streamlined workflow and potential for cost reduction.

Next Steps

• Enrollment of WATER IV patients is expected to continue.
• The company will continue to analyze data from the PRCT001 and PRCT002 studies.
• The company will pursue a specific treatment indication for prostate cancer.
• The company will continue to monitor the adoption of the HYDROS system and its impact on hospital efficiency.

Key Dates

Keywords

Aquablation, Prostate Cancer, BPH, HYDROS Robotic System, WATER IV Trial, PRCT001, PRCT002, PROCEPT BioRobotics, Urology